MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

Начало・Списък с акции・Altimmune Inc

Altimmune Inc

Затворен

3.27 0.93

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.23

Максимум

3.31

Ключови измерители
By Trading Economics
Приходи	-8.3M -27M
Продажби	21K 26K
Марж на печалбата	-105,223.077
Служители	57
EBITDA	-10M -29M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+317.96% upside

Дивиденти
By Dow Jones
Следващи печалби	12.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-88M 433M
Предишно отваряне	2.34
Предишно затваряне	3.27

Техническа оценка

By Trading Central

Увереност

Bullish Evidence

5.365 / 6.0486 Подкрепа & съпротива

Altimmune Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

13.04.2026 г., 23:25 ч. UTC

Значими събития в новините

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy -- Update

13.04.2026 г., 22:45 ч. UTC

Значими събития в новините

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy

13.04.2026 г., 18:03 ч. UTC

Печалби

Louis Vuitton Owner Logs Weak Sales as Middle East War Takes Toll -- 2nd Update

13.04.2026 г., 23:58 ч. UTC

Печалби

Review & Preview: Earnings Time -- Barrons.com

13.04.2026 г., 23:49 ч. UTC

Пазарно говорене

Nikkei May Rise After Overnight Gains on Wall Street -- Market Talk

13.04.2026 г., 23:33 ч. UTC

Пазарно говорене

Значими събития в новините

Gold Edges Higher Amid Dollar Weakness -- Market Talk

13.04.2026 г., 23:20 ч. UTC

Пазарно говорене

Uranium Stocks Seen Benefiting From Energy Security Concerns -- Market Talk

13.04.2026 г., 23:01 ч. UTC

Печалби

Aura: Capex Guidance Revised From $111M and $130M to New Range of $262M and $314M >AURA33.SA.BR

13.04.2026 г., 23:01 ч. UTC

Печалби

Aura Minerals: Announces Update to Capex Guidance Including Construction of the Era Dorada Project

13.04.2026 г., 23:01 ч. UTC

Печалби

Aura: Will Update Cap Expenditure Guidance to Include the Project's Construction Phase >AURA33.SA.BR

13.04.2026 г., 22:21 ч. UTC

Придобивния, сливания и поглъщания

Chevron Swaps Offshore Gas Stakes to Boost Venezuelan Heavy-Oil Footprint -- Update

13.04.2026 г., 21:53 ч. UTC

Печалби

MarketWise, Inc.: Affirms FY 2026 Guidance, Including Div Target to Class A Hldrs of $1.80 per Shr

13.04.2026 г., 21:53 ч. UTC

Печалби

MarketWise, Inc.: Paid Subscribers Were 381,000 at March 31 Compared to 374,000 at Dec 31, 2025, Active Free Subscribers Were 2.0M at March 31 >MKTW

13.04.2026 г., 21:53 ч. UTC

Печалби

MarketWise, Inc.: 1Q Billings Increased Approximately 15% Yr-over-Yr to Approximately $81M

13.04.2026 г., 21:53 ч. UTC

Печалби

MarketWise, Inc.: Preliminary Selected Unaudited 1Q Paid Subscribers Returning to Growth

13.04.2026 г., 21:26 ч. UTC

Значими събития в новините

U.S. Oil Blockade Is Set to Boost American Exports -- and Prices at the Pump -- WSJ

13.04.2026 г., 21:23 ч. UTC

Печалби

Johnson & Johnson Earnings: Oncology Powers Growth, but Talc Lawsuits Persist -- Barrons.com

13.04.2026 г., 21:16 ч. UTC

Печалби

Goldman Sachs Reports Record Quarter in Banking and Trading -- 4th Update

13.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Значими събития в новините

Basic Materials Roundup: Market Talk

13.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

13.04.2026 г., 20:34 ч. UTC

Печалби

Victory Capital: 1Q Long-Term AUM Net Flows of -$457M >VCTR

13.04.2026 г., 20:34 ч. UTC

Печалби

Victory Capital: March Avg Total AUM Was $315.3B, Avg Other Assets $3.2B, Avg Total Client Assets $318.5B >VCTR

13.04.2026 г., 20:34 ч. UTC

Печалби

Victory Capital Holdings, Inc.: Total Assets Under Management of $309.8B, Other Assets $3.3B, Total Client Assets of $313.1B as of March 31 >VCTR

13.04.2026 г., 19:59 ч. UTC

Пазарно говорене

Canada Consumers Sour Prior to Big Energy-Price Jump -- Market Talk

13.04.2026 г., 19:50 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Futures Pull Back From Highs on Hopes for Talks -- Market Talk

13.04.2026 г., 19:27 ч. UTC

Пазарно говорене

Значими събития в новините

Correction to Precious Metals Market Talk on April 9

13.04.2026 г., 19:14 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Settle Lower on Mild Weather -- Market Talk

13.04.2026 г., 18:59 ч. UTC

Пазарно говорене

Значими събития в новините

Fed's Goolsbee: Don't Be Surprised If Consumer Confidence Sours -- Market Talk

13.04.2026 г., 18:59 ч. UTC

Пазарно говорене

Значими събития в новините

Fed's Goolsbee: Oil Shows People Expect Short Term Conflict in Iran -- Market Talk

13.04.2026 г., 18:43 ч. UTC

Пазарно говорене

Precious Metals Lose Ground as U.S. Blockade in Hormuz Gets Underway -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Altimmune Inc Прогноза

Ценова цел

By TipRanks

317.96% нагоре

12-месечна прогноза

Среден 13.5 USD 317.96%

Висок 25 USD

Нисък 4.01 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за Altimmune Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

6 ratings

Купи

Задържане

Продай

Според 6 анализатори, дали борсови рейтинги на Altimmune Inc през последните 3 месеца.

Техническа оценка

By Trading Central

5.365 / 6.0486Подкрепа & съпротива

Recent bullish events outweigh bearish events.

All events are bearish.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Altimmune Inc

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.